Nov 27, 2024
In this CME podcast, Dr. Andrew Cutler interviews Dr. Jonathan Meyer about the history of muscarinic receptor science in schizophrenia and how that informs the mechanisms of action of novel muscarinic-targeting drugs for this disorder. They also discuss the efficacy and safety of these drugs and provide practical strategies for prescribing xanomeline-trospium.
Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study.
Learning Objectives: After completing this educational activity, you should be better able to:
Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Activity Overview: This activity is available
with audio and is best supported via a computer or device with
current versions of the following browsers: Mozilla Firefox, Google
Chrome, or Safari. A PDF reader is required for print publications.
A post-test score of 70% or higher is required to receive CME/CE
credit.
Estimated Time to Complete: 1 hour
Released: November 27, 2024*
Expiration: November 26, 2027
*NEI maintains a record of participation for six (6)
years.
CME/CE Credits and Certificate Instructions:
After listening to the podcast, to take the optional posttest and
receive CME/CE credit, click: https://nei.global/POD24-SCHIZ01
Credit Designations: The following are being
offered for this activity:
Peer Review: The content was peer-reviewed by an MD specializing in psychiatry and psychopharmacology — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity.
Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships.
Faculty Author / Presenter
Andrew J. Cutler, MD
Clinical Associate Professor, Department of Psychiatry and
Behavioral Sciences, Norton College of Medicine, State University
of New York Upstate Medical University, Syracuse, NY
Chief Medical Officer, Neuroscience Education Institute,
Malvern, PA
Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome,
Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel,
Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular,
Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye,
MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven,
Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion),
Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics
Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome,
BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen,
Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion),
Supernus, Takeda, Teva, Tris Pharma, Vanda
Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom
Biosciences
Faculty Author / Presenter
Jonathan M. Meyer, MD
Voluntary Clinical Professor, Department of Psychiatry,
University of California, San Diego School of Medicine, La Jolla,
CA
Consultant/Advisor: AbbVie, Alkermes, Bristol Myers Squibb,
Intra-Cellular, Neurocrine, Sumitomo, Teva
Speakers Bureau: AbbVie, Alkermes, Axsome, Bristol Myers Squibb,
Intra-Cellular, Neurocrine, Teva
The remaining Planning Committee members, Content Editors, Peer
Reviewer, and NEI planners/staff have no financial relationships to
disclose. NEI planners and staff include Caroline O’Brien, Gabriela
Alarcón, PhD, Meghan M. Grady, BA, Andrea Zimmerman, EdD, CHCP, and
Brielle Calleo.
Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.
Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me.
Contact Us: For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com.
Support: This activity is supported by an educational grant from Bristol Myers Squibb.